Karyopharm Therapeutics Inc. (KPTI) Downgraded to Neutral by HC Wainwright & Co.

Market Context

Karyopharm Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $1.92 with a market capitalization of $59.5M.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow HC Wainwright & Co.'s research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Karyopharm Therapeutics Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 31, 2026	Piper Sandler	Overweight	N/A
Jul 31, 2026	HC Wainwright & Co.	Neutral	N/A
May 06, 2026	HC Wainwright & Co.	Buy	N/A
Apr 27, 2026	Piper Sandler	Overweight	N/A
Mar 30, 2026	Piper Sandler	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View KPTI Stock Page